Background
Methods
Patients and study design
Diagnostic criteria
Inclusion and exclusion criteria
Blood collection and storage
RNA isolation and preparation
miRNA array analysis
Reverse transcription quantitative real-time polymerase chain reaction (RT-qPCR) analysis
Statistical analysis
Results
Patient clinicopathological information
Variable | CAD (n = 15) | Without CAD (n = 5) | ||
---|---|---|---|---|
SA (n = 5) | NSTE-ACS (n = 5) | STEMI (n = 5) | ||
Age (years, mean ± SD) | 55.8 ± 4.15 | 57.4 ± 11.19 | 52.8 ± 10.56 | 52.4 ± 13.28 |
Sex (male, n) | 5 | 5 | 5 | 5 |
Risk factors (n) | ||||
Hypertension | 4 | 4 | 2 | 3 |
Dyslipidemia | 5 | 3 | 4 | 3 |
Active smoker | 4 | 3 | 5 | 1 |
Medications (n) | ||||
Antiplatelet agents | 5 | 5 | 5 | 0 |
β-Blockers | 4 | 3 | 3 | 0 |
CCB | 2 | 1 | 1 | 1 |
ACEI/ARB | 4 | 4 | 4 | 2 |
Statins | 5 | 5 | 5 | 1 |
Variable | CAD (n = 56) | Without CAD (n = 16) | ||
---|---|---|---|---|
SA (n = 20) | NSTE-ACS (n = 18) | STEMI (n = 18) | ||
Age (years, mean ± SD) | 55.8 ± 9.15 | 56.44 ± 8.78 | 53.50 ± 10.56 | 52.5 ± 13.50 |
Sex (male, n) | 12 | 15 | 16 | 9 |
Risk factors (n) | ||||
Hypertension | 14 | 15 | 13 | 11 |
Dyslipidemia | 12 | 13 | 11 | 8 |
DM | 9 | 10 | 9 | 7 |
Active smoker | 12 | 15 | 14 | 8 |
Medications (n) | ||||
Antiplatelet agents | 12 | 16 | 18 | 0 |
β-Blockers | 13 | 11 | 9 | 9 |
Statins | 18 | 16 | 12 | 8 |
miRNA array analysis
miRNAs | STEMI versus without CAD | STEMI versus SA | STEMI versus NSTE-ACS | ||||||
---|---|---|---|---|---|---|---|---|---|
Fold change |
P value | Regulation | Fold change |
P value | Regulation | Fold change |
P value | Regulation | |
miR-941
| 5.305 | 0.007 | Up | 4.544 | 0.003 | Up | 5.032 | 0.002 | Up |
miR-182-5p
| 2.331 | 0.013 | Down | 2.005 | 0.042 | Down | 2.121 | 0.024 | Up |
miR-363-3p
| 2.012 | 0.007 | Down | 2.016 | 0.018 | Down | 2.071 | 0.048 | Up |
hsa-mir-941-1
| 1.895 | 0.036 | Up | 2.051 | 0.001 | Up | 2.008 | 0.001 | Up |
hsa-mir-941-2
| 1.895 | 0.036 | Up | 2.051 | 0.001 | Up | 2.008 | 0.001 | Up |
hsa-mir-941-3
| 1.895 | 0.036 | Up | 2.051 | 0.001 | Up | 2.008 | 0.001 | Up |
hsa-mir-941-4
| 1.895 | 0.036 | Up | 2.051 | 0.001 | Up | 2.008 | 0.001 | Up |
hsa-miR-6798-5p
| 2.049 | 0.015 | Up | 1.866 | 0.019 | Up | 2.041 | 4.32E-04 | Up |
hsa-miR-4419a
| 1.737 | 0.013 | Up | 1.717 | 0.006 | Up | 1.851 | 9.32E-05 | Up |
hsa-miR-296-3p
| 1.811 | 0.031 | Up | 2.209 | 0.012 | Up | 1.726 | 0.109 | Up |
hsa-miR-1227-5p
| 1.549 | 0.013 | Up | 1.629 | 0.039 | Up | 1.653 | 0.147 | Up |
hsa-miR-4656
| 1.908 | 0.005 | Up | 1.617 | 0.025 | Up | 1.232 | 0.459 | Up |
hsa-miR-3064-3p
| 1.765 | 0.037 | Down | 1.529 | 0.001 | Down | 1.033 | 0.738 | Down |
Gene ontology (GO) analysis
Pathway analysis
qRT-PCR
Receiver operating characteristic (ROC) curve analysis
miR-941
| AUC | 95% CI |
P value |
---|---|---|---|
Non-ACS versus ACS | 0.734 | 0.619–0.848 | 0.001 |
Without CAD versus STEMI | 0.896 | 0.779–1.000 | 0.000 |
SA versus STEMI | 0.808 | 0.670–0.947 | 0.001 |
NSTE-ACS versus STEMI | 0.781 | 0.622–0.939 | 0.004 |